Clinical and pathological features and treatment of nine cases of gastrointestinal composite gangliocytoma/neuroma and neuroendocrine tumor

Table 1 Clinicopathologic characteristics, treatment and follow-up of 9 composite gangliocytoma/neuroma and neuroendocrine tumors

No.	Sex	Age (year)	Clinical symptoms	Site	Size (cm)	Incisal margin	Metastasis	Recurrence	Treatment	Follow-up (month)
1	M	66	Abdominal distension	Descending part of duodenum	4.5	N	N	N	ESD	10
2	M	56	Abdominal distension	Descending part of duodenum	1.4	N	N	N	ERCP	14
3	M	54	N	Descending part of duodenum	2	N	N	N	Partial duodenectomy	36
4	F	72	Abdominal pain	Descending part of duodenum	1.8	N	Lymph node	N	Pancreaticoduodenectomy	40
5	F	40	Abdominal pain	Horizontal part of the duodenum	1.5	N	N	N	Local resection of ampullary tumor	41
6	F	23	Abdominal pain	Bulb-descending junction of the duodenum	1.2	N	N	N	EMR	53
7	M	52	N	Descending part of duodenum	1.7	N	N	N	ERCP	69
8	M	38	N	Horizontal part of the duodenum	3.7	N	N	N	Pancreaticoduodenectomy	69
9	F	60	N	Rectum	1.3	N	N	N	ESD	40

M: Male; F: Female; N: Negative; ESD: Endoscopic submucosal dissection; ERCP: Cholangiopancreatography-guided papillectomy; EMR: Endoscopic mucosal resection.

Table 2 Immunohistochemical findings of 9 composite gangliocytoma/neuroma and neuroendocrine tumors

No.	Ki-67 (%)	CK-pan	CgA	CD56	Syn	S-100	SOX10
1	1	P	P	P	P	P	P
2	3	P	P	N	P	P	P
3	1	P	P	P	P	P	P
4	1	P	P	P	P	P	P
5	3	P	P	P	P	P	P
6	3	N	P	P	P	P	N
7	2	P	P	P	P	P	N
8	2	P	P	P	P	P	N
9	1	N	P	N	P	P	N

Ki-67 indices were determined based on a 500-cell count in an expression hotspot. CK-pan: Pan-cytokeratin; CgA: Positive expression of chromogranin A; Syn: Synaptophysin; SOX10: SRY-box transcription factor 10; P: Positive; N: Negative.